Alto Neuroscience (ANRO) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $21.94, -3.01% vs the prior close of $22.62.
- Volume 648.32K shares, 1.1x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
ANRO slides 3.0% to $21.94. Closed at $21.94, -3.01% vs the prior close of $22.62. Day range $21.71–$22.63, opened at $21.97.
ANRO daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — ANRO slides 3.0% to $21.94
- Closed at $21.94, -3.01% vs the prior close of $22.62. Day range $21.71–$22.63, opened at $21.97.
- Volume was 648.32K shares, 1.1x its 50-day average of 578.13K.
- Price is -26.9% vs its 50-day average ($30.01) and -8.3% vs its 200-day average ($23.93).
- 52-week range $5.71–$37.48; today's close sits at 51% of that range, 41.5% below the 52-week high.
Oct 15, 2026 — ANRO jumps 4.2% to $22.62
- Closed at $22.62, +4.19% vs the prior close of $21.71. Day range $21.62–$23.31, opened at $21.92.
- Volume was 529.90K shares, 0.9x its 50-day average of 572.51K.
- Price is -25.0% vs its 50-day average ($30.14) and -5.4% vs its 200-day average ($23.91).
- 52-week range $5.56–$37.48; today's close sits at 53% of that range, 39.6% below the 52-week high.
Oct 14, 2026 — ANRO dips 1.7% to $21.71, a 3-month low on 4.2x normal volume
- Closed at $21.71, -1.72% vs the prior close of $22.09. Day range $21.32–$22.59, opened at $21.83.
- Volume was 2.28M shares, 4.2x its 50-day average of 538.01K — unusually heavy trading.
- Price is -28.2% vs its 50-day average ($30.25) and -9.1% vs its 200-day average ($23.89).
- 52-week range $5.22–$37.48; today's close sits at 51% of that range, 42.1% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — ANRO slides 8.5% to $22.09, a 3-month low
- Closed at $22.09, -8.53% vs the prior close of $24.15. Day range $22.07–$24.20, opened at $24.04.
- Volume was 661.80K shares, 1.2x its 50-day average of 532.96K.
- Price is -27.3% vs its 50-day average ($30.38) and -7.5% vs its 200-day average ($23.88).
- 52-week range $5.22–$37.48; today's close sits at 52% of that range, 41.1% below the 52-week high.
Oct 12, 2026 — ANRO dips 0.9% to $24.15
- Closed at $24.15, -0.90% vs the prior close of $24.37. Day range $23.85–$25.25, opened at $24.34.
- Volume was 390.30K shares, 0.7x its 50-day average of 531.63K.
- Price is -20.8% vs its 50-day average ($30.48) and +1.2% vs its 200-day average ($23.86).
- 52-week range $5.22–$37.48; today's close sits at 59% of that range, 35.6% below the 52-week high.
Oct 9, 2026 — ANRO rises 1.4% to $24.37
- Closed at $24.37, +1.41% vs the prior close of $24.03. Day range $23.81–$25.11, opened at $24.00.
- Volume was 649.40K shares, 1.2x its 50-day average of 525.63K.
- Price is -20.2% vs its 50-day average ($30.54) and +2.2% vs its 200-day average ($23.84).
- 52-week range $5.22–$37.48; today's close sits at 59% of that range, 35.0% below the 52-week high.
Oct 8, 2026 — ANRO rises 2.2% to $24.03
- Closed at $24.03, +2.17% vs the prior close of $23.52. Day range $22.81–$24.05, opened at $23.03.
- Volume was 409.80K shares, 0.8x its 50-day average of 523.44K.
- Price is -21.5% vs its 50-day average ($30.63) and +0.9% vs its 200-day average ($23.82).
- 52-week range $5.22–$37.48; today's close sits at 58% of that range, 35.9% below the 52-week high.
Oct 7, 2026 — ANRO dips 0.7% to $23.52, a 3-month low, 7 down days in a row
- Closed at $23.52, -0.72% vs the prior close of $23.69. Day range $23.33–$24.42, opened at $23.39.
- Volume was 347.90K shares, 0.7x its 50-day average of 524.70K.
- Price is -23.3% vs its 50-day average ($30.68) and -1.2% vs its 200-day average ($23.80).
- 52-week range $5.22–$37.48; today's close sits at 57% of that range, 37.2% below the 52-week high.
- That makes 7 straight losses.
Oct 6, 2026 — ANRO dips 1.3% to $23.69, a 3-month low, 6 down days in a row
- Closed at $23.69, -1.33% vs the prior close of $24.01. Day range $23.50–$24.70, opened at $24.06.
- Volume was 576.30K shares, 1.1x its 50-day average of 523.17K.
- Price is -23.0% vs its 50-day average ($30.76) and -0.4% vs its 200-day average ($23.78).
- 52-week range $5.22–$37.48; today's close sits at 57% of that range, 36.8% below the 52-week high.
- That makes 6 straight losses.
Oct 5, 2026 — ANRO slides 3.2% to $24.01, a 3-month low, 5 down days in a row
- Closed at $24.01, -3.19% vs the prior close of $24.80. Day range $23.80–$25.85, opened at $24.63.
- Volume was 550.30K shares, 1.1x its 50-day average of 518.07K.
- Price is -22.2% vs its 50-day average ($30.84) and +1.1% vs its 200-day average ($23.75).
- 52-week range $4.71–$37.48; today's close sits at 59% of that range, 35.9% below the 52-week high.
- That makes 5 straight losses.
Oct 2, 2026 — ANRO dips 2.0% to $24.80, a 3-month low, 4 down days in a row
- Closed at $24.80, -2.02% vs the prior close of $25.31. Day range $23.87–$26.10, opened at $25.64.
- Volume was 660.70K shares, 1.3x its 50-day average of 510.02K.
- Price is -19.7% vs its 50-day average ($30.90) and +4.6% vs its 200-day average ($23.72).
- 52-week range $4.04–$37.48; today's close sits at 62% of that range, 33.8% below the 52-week high.
- That makes 4 straight losses.
ANRO latest news & SEC filings
Every SEC filing by or about ANRO in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Smith Nicholas Conrad converted options/RSUs into 55,000 shares at $2.32 (≈$127.60K) on Oct 2, 2026; now holds 79,060
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Smith Nicholas Conrad converted options/RSUs into 56,455 shares at $2.35 (≈$132.67K) on Sep 29, 2026; now holds 80,515
- Smith Nicholas Conrad converted options/RSUs into 54,375 shares at $2.35 (≈$127.78K) on Sep 29, 2026; now holds 134,890
- Smith Nicholas Conrad sold 110,830 shares at $26.58 (≈$2.95M) on Sep 29, 2026; now holds 24,060
- Smith Nicholas Conrad converted options/RSUs into 24,056 shares at $2.35 (≈$56.53K) on Sep 30, 2026; now holds 48,116
- Smith Nicholas Conrad sold 23,170 shares at $25.78 (≈$597.29K) on Sep 30, 2026; now holds 24,946
- Smith Nicholas Conrad sold 886 shares at $26.87 (≈$23.81K) on Sep 30, 2026; now holds 24,060
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 29, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 27, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$27.64M (prior year -$17.71M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.65 (prior year -$0.65) ( vs Jun 30, 2025)
Aug 12, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 27, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 20, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
Jul 14, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Jul 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 8.01 — Reported other events the company considers important.
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade ANRO
- Last results release: Aug 12, 2026 (8-K Item 2.02). Previous ones: Jul 13, 2026, May 13, 2026, Mar 16, 2026. Based on that rhythm, the next report is likely around Nov 11, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.55% (largest 10.7%).
- Liquidity: about 651.11K shares (≈$14.29M) trade per day on average.
- 52-week position: $21.94 vs a range of $5.71–$37.48 (51% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Aug 27, 2026; 10-Q Aug 12, 2026; 8-K Aug 12, 2026.
- Share count: 39.24M shares outstanding (Aug 7, 2026), +44.9% vs a year earlier — notable dilution.
- Listing: NYSE · industry: Pharmaceutical Preparations.
ANRO market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 21.97 | 22.63 | 21.71 | 21.94 | 648.32K |
| Oct 15, 2026 | 21.92 | 23.31 | 21.62 | 22.62 | 529.90K |
| Oct 14, 2026 | 21.83 | 22.59 | 21.32 | 21.71 | 2.28M |
| Oct 13, 2026 | 24.04 | 24.20 | 22.07 | 22.09 | 661.80K |
| Oct 12, 2026 | 24.34 | 25.25 | 23.85 | 24.15 | 390.30K |
| Oct 9, 2026 | 24.00 | 25.11 | 23.81 | 24.37 | 649.40K |
| Oct 8, 2026 | 23.03 | 24.05 | 22.81 | 24.03 | 409.80K |
| Oct 7, 2026 | 23.39 | 24.42 | 23.33 | 23.52 | 347.90K |
| Oct 6, 2026 | 24.06 | 24.70 | 23.50 | 23.69 | 576.30K |
| Oct 5, 2026 | 24.63 | 25.85 | 23.80 | 24.01 | 550.30K |
| Oct 2, 2026 | 25.64 | 26.10 | 23.87 | 24.80 | 660.70K |
| Oct 1, 2026 | 25.50 | 26.49 | 25.12 | 25.31 | 575.80K |
| Sep 30, 2026 | 26.87 | 27.41 | 25.53 | 25.53 | 891.60K |
| Sep 29, 2026 | 26.44 | 27.42 | 25.75 | 26.58 | 763.40K |
| Sep 28, 2026 | 26.36 | 27.76 | 25.89 | 26.66 | 587.00K |
| Sep 25, 2026 | 27.36 | 27.61 | 26.48 | 26.49 | 366.30K |
| Sep 24, 2026 | 27.51 | 27.91 | 26.39 | 27.18 | 788.40K |
| Sep 23, 2026 | 30.39 | 30.61 | 26.41 | 27.50 | 639.90K |
| Sep 22, 2026 | 30.71 | 31.46 | 30.17 | 30.78 | 347.10K |
| Sep 21, 2026 | 30.64 | 30.81 | 29.80 | 30.63 | 357.80K |
About Alto Neuroscience
Alto Neuroscience (ANRO) is listed on the NYSE and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in MOUNTAIN VIEW, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1999480.
ANRO board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Christopher Nixon Cox | Director | May 14, 2026 |
| Andrew Dreyfus | Director | May 14, 2026 |
| Amit Etkin | PRESIDENT AND CEO | May 15, 2026 |
| Husseini Manji | Director | May 14, 2026 |
| Andrew Craig Miller | Director | May 29, 2026 |
| Ramiro Sanchez | Director | May 14, 2026 |
| Gwill York | Director | May 14, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Amit Etkin | PRESIDENT AND CEO | May 15, 2026 |
| Jr. Michael Conick Hanley | CHIEF OPERATING OFFICER | Feb 13, 2026 |
| Adam Savitz | CHIEF MEDICAL OFFICER | Feb 13, 2026 |
| Nicholas Conrad Smith | CHIEF FINANCIAL OFFICER & CBO | Mar 3, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
ANRO financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-63.24M | -2.19 | $-51.77M |
| Dec 31, 2024 | — | $-61.43M | -2.50 | $-47.42M |
| Dec 31, 2023 | — | $-36.30M | -9.73 | $-33.45M |
Latest balance sheet: total assets $254.07M, total liabilities $34.82M, cash $243.73M (as of Jun 30, 2026).
ANRO earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 12, 2026 | 8-K Item 2.02 (results) | $29.18 |
| Jul 13, 2026 | 8-K Item 2.02 (results) | $28.03 |
| May 13, 2026 | 8-K Item 2.02 (results) | $22.85 |
| Mar 16, 2026 | 8-K Item 2.02 (results) | $24.29 |
| Nov 12, 2025 | 8-K Item 2.02 (results) | $14.20 |
| Aug 13, 2025 | 8-K Item 2.02 (results) | $3.13 |
| May 14, 2025 | 8-K Item 2.02 (results) | $2.20 |
| Mar 20, 2025 | 8-K Item 2.02 (results) | $2.69 |
| Feb 3, 2025 | 8-K Item 2.02 (results) | $4.18 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $4.50 |
| Aug 13, 2024 | 8-K Item 2.02 (results) | — |
| May 14, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on ANRO
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.